illumina board of directors

Mr. Huber is Senior Vice President at Google Inc. where he works at Google [x]. Illumina, Inc. ILMN announced that its wholly-owned subsidiary, GRAIL, entered a collaboration with the U.S. Department of Veterans Affairs (VA) Veterans Health . Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates (NEA) and a resident fellow at the American Enterprise Institute (AEI). Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a NYSE-listed diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. Our Board of Directors is composed of leaders and visionaries from the industry. A target board can adopt a poison pill to prevent a bidder from completing a hostile takeover. Tweet. The Institute has grown in . Over 24 years, Mr. Ashe held a variety of positions with increasing responsibility at Cognos Incorporated, a business intelligence and performance management software company. Mr. Huber is Senior Vice President at Google Inc. where he . Expanded NIPT: Expanded Screening - Extensive Insights, Earlier Planning. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center. During his tenure as CEO Jay took Illumina from $1.3 million in sales in 2000 to $2.2 billion in 2015. Christian Henry. Dorsa has held a number of senior management positions at Merck and Co . 75 breakthrough innovations and our simplest workflow yet. April 18, 2005 7:00 AM UTC . A medical oncologist and global health professional, Vinona moved from direct patient care to industry in 2013. WIR Staff. #Illumina's DNA" Shantanu Ghosh "Francis was my boss for a several years (directly and then indirectly). ILLUMINA BOARD OF DIRECTORS TO REVIEW . "Through active participation in a simulated community, students develop an understanding of . . Security holders may obtain information regarding the names, affiliations and interests of Illumina's directors and executive officers in Illumina's Annual Report on Form 10-K for the year ended January 2, 2011, which was filed with the SEC on February . All Selection & Planning Tools. Biztown is JA's experiential-based elementary school capstone program. San Diego's Moore Cancer Center and serves on the Board of . Former CEO, Chairman of Illumina, Inc. Jay Flatley Jay led Illumina as CEO from 1999 until 2016, served as Executive Chairman from July 2016 to December 2019, and now serves as Chairman of the Board of Directors. Mr. Hinshaw has extensive experience of transforming organizations in a wide range of industries. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. Illumina announced that Jay Flatley will step down from the company's board of directors and John Thompson will replace him as chairman of the board, effective May 26. Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. Illumina, Inc. is an American company. Grail co-founder and previous Illumina board member Jeff Huber has . Dr. Scott Gottlieb, former U.S. FDA Commissioner, joins Illumina's Board of Directors Contacts Illumina, Inc. Investors: Jacquie Ross, CFA 858-255-5243 ir@illumina.com or Media: Tina Amirkiai . The DRAGEN Platform enables labs of all sizes and disciplines to do more with their genomic data. Eastham previously served as a director of Illumina, Inc. from July 2004 to May 2019; MorphoSys AG from May 2012 to May 2017; Trius Therapeutics, Inc. from 2009 until its sale in 2013; . She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a privately-held pharmaceuticals company, since September 2019. On July 5, 2016, Jay Flatley, who had been CEO since 1999, assumed the role of executive chairman of the board of directors. John Frank is Chief Public Affairs Officer where he directly advises Illumina's CEO, Board of Directors, General Counsel, and Executive Leadership Team, offering expertise and assessing geopolitical and policy implications of Illumina's business and strategies. By not engaging with Roche, Illumina reinforces . Dorsa has held a number of senior management positions at Merck and Co . Board Director Citrix 2014 - 2016 2 years. This Smart News Release features multimedia. Read Biography. See the breakdown of the total annual compensation for Karin Eastham for being a board member of ILLUMINA, INC., as well as other members of the Board of Directors for ILLUMINA, INC. All interested parties who wish to communicate with the Board of Directors or any of the non-employee directors may do so by sending a letter to the Corporate Secretary, Illumina, Inc., 5200 Illumina Way, San Diego, California 92122, and should specify the intended recipient or recipients. Dr. Gottlieb is currently a special partner at the venture . Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates (NEA) and a resident fellow at the American Enterprise Institute (AEI . Siegel is Chief Innovation Officer at General Electric (GE) and CEO of GE Ventures. Symantec 7 years 10 months . Francis deSouza, currently President, will be appointed President and Chief Executive Officer on the same date and will continue to serve on the Illumina Board of Directors. We are dedicated to improving human health by unlocking the power of the genome. SAN DIEGO-- (BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. He oversaw the company's expansion . Jun 1, 2022 9:56AM EDT. One of Apple's most important execs just joined the board of a $25 billion genetics company. Illumina, looking ahead to its April 18 annual meeting, also is asking stockholders to vote in support of Illumina's directors at the meeting. Feb. 20, 2017- Illumina , Inc. (NASDAQ: ILMN) announced today that John W. Thompson will join the company's Board of Directors on May 3, 2017 , bringing extensive technology leadership experience to the company. Deepa R. Pakianathan, Ph.D., has served as a member of our board of directors since July 2020. Illumina, Inc. (NASDAQ: ILMN) today announced that Jay Flatley, current Chairman and CEO, will assume the role of Executive Chairman of the Board of D Illumina is the largest genome sequencing and array-based solutions provider for genomic analysis in the world. Welcome to Immense Discovery Power. Rockell N. Hankin. Mohan Maheswaran. David Walt - Founder, Director and Member of Nominating and Corporate Governance Committee: Profile: Philip Schiller - Director: The result is that roughly one-third of Illumina's directors are up for election in any given year. Robert Ashe has served as a member of our board of directors since December 2014 and as our Lead Independent Director since May 2015. Illumina board of directors update. In addition to its cash tender offer, Roche has nominated a slate of highly qualified, independent candidates for election to Illumina's Board of Directors and proposed certain other matters for the consideration of Illumina's shareholders at Illumina's 2012 annual meeting, which if adopted, would result in Roche-nominated directors comprising . Delivering Value to Investors. #Illumina's DNA" Shantanu Ghosh "Francis was my boss for a several years (directly and then indirectly). has joined the company's Board of Directors, effective February 4, 2020. ILLUMINA BOARD OF DIRECTORS TO REVIEW . SAN DIEGO-- (BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) (the "Company") today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company's new Chair of the Board. Frances Arnold, a Caltech professor who serves on the board of directors of Illumina, the influential San Diego life sciences company, has been chosen to share this year's Nobel Prize in chemistry. Board of Directors . Garry O. Ridge joined WD-40 Company in 1987 as managing director, WD-40 Company (Australia) Pty. Bowman has served on our board of directors since May 2019. SAN DIEGO -- (BUSINESS WIRE)--Jul. These changes will be effective as of the Company's Annual Shareholder Meeting on May 26, 2021. The conference call will begin at 2 p.m. Pacific Time (5 p.m. Eastern Time) on Thursday, May 5, 2022. He also has served on the boards of Sysco Foods and DocuSign. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel . Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina SAN DIEGO --(BUSINESS WIRE)--Feb. 20, 2017-- Illumina , Inc. (NASDAQ: ILMN) announced today that John W. Thompson will join the company's Board of Directors on May 3, 2017 , bringing extensive technology leadership . The Future of Bio/Pharmaceutical Analysis: Registration for our online summit is now open! Software & Analysis She has either lived, worked or traveled in . 31, 2014-- Illumina, Inc. (NASDAQ:ILMN) today announced that Jeff Huber has joined the company's Board of Directors. Illumina just announced the NovaSeq 6000 kit to make whole genome sequencing more accessible. Chairman of the Board and Nominating and Governance Committee Chair. Learn More In addition to being Chairman and Acting CEO of Zymergen, Jay serves as a member of the Boards of Denali Therapeutics Inc. and Coherent Inc., is an advisory board member for U.C. Flatley led Illumina as CEO from 1999 to 2016 and served as executive chair . SAN DIEGO--(BUSINESS WIRE)--Jan. 28, 2016-- Illumina, Inc. (NASDAQ: ILMN) today announced that Dr. Frances Arnold has joined the company's Board of Directors. Illumina, Inc. ( ILMN) today announced that Jeff Huber has joined the company's Board of Directors. As Illumina (ILMN 4.06%) moves more into the clinical diagnosis space, the DNA-sequencing specialist has made a big addition to its board of directors: Scott Gottlieb, a former commissioner of the . By Bio-IT World Staff . Member of the Compensation Committee. NovaSeq 6000 Sequencing System is by far our most powerful instrument, designed to adapt to your needs. Ms. Dorsa has been a director since January 2017. He is also a scientific advisor to MiNDERA Corp. and Luna DNA. All such communications will be forwarded to the . Interested parties may access the live teleconference through the Investor Info section of Illumina's website under the "Company" tab at www.illumina.com. March 18, 2021 | Illumina has announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company's new Chair of the Board. April 18, 2005 7:00 AM UTC Learn More Dr. Scott Gottlieb, joined Illumina's board of directors back in February. Swiss drugmaker Roche in January submitted a slate of four nominees for Illumina's board of directors, and proposed five alternate nominees. "It has been a tremendous honor to work with the Illumina team during the past . . Tuesday, February 21, 2017. He is renowned for sequencing the first complete human genome and construction of the first synthetic cell. Burvill. Mar. Mr. Huber joined Google in 2003 and led development for . Symantec 7 years 10 months . Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a NYSE-listed diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. During his tenure as CEO, he took the company from $1.3 million in sales in 2000 to $2.2 billion in 2015, representing a compound annual growth rate of 64 percent. has joined the company's Board of Directors, effective February 4, 2020. During his career, Jeff Brown has worked for companies that specialize in semiconductors, broadcasting and . - USA, CA - Mammoth Biosciences, the company behind the world's first CRISPR-based disease detection platform, today announced an oversubscribed round of $45 million in its Series B funding round led by Decheng Capital with participation from Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8, aMoon, and others.